NCT07752953 — ZSky Biotech neoantigen vaccine trial
Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors
Registry record
| Registry ID | NCT07752953 ↗ |
|---|---|
| Lead sponsor | ZSky Biotech Inc |
| Collaborators | — |
| Phase | Phase NA |
| Status | Recruiting |
| Indication | Advanced Solid Tumor, Cancer, Malignant Solid Tumor |
| Enrollment | 100 participants (target) |
| Start date | 2026-05-01 |
| Primary completion | 2029-08-10 (est.) |
| Last registry update | 7 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07752953), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07752953?
NCT07752953 (Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors) is registered on ClinicalTrials.gov as Phase NA, sponsored by ZSky Biotech Inc.
Is NCT07752953 recruiting?
As of the 2026-08-07 registry update, NCT07752953 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07752953?
The lead sponsor is ZSky Biotech Inc.
What condition does NCT07752953 study?
The registered conditions are Advanced Solid Tumor, Cancer, Malignant Solid Tumor. Primary completion is listed as 2029-08-10 (estimated).
Are results available for NCT07752953?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07752953.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.